Melbourne, 9 October, 2018 – CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunami relief efforts.
The donation will help provide urgently needed aid to people and communities affected by a powerful earthquake followed by a tsunami in Sulawesi.
CSL’s donation will be channelled through the Australian Red Cross as well as the Swiss National Donation Day for Indonesia.
“Our thoughts are with the thousands of people in Sulawesi who have been affected by these catastrophic events. During this difficult time, we acknowledge the people working tirelessly in support of relief efforts,” said Paul Perreault, CSL Limited CEO & Managing Director.
In addition to CSL’s corporate donation, the company will match dollar-for-dollar all employee donations to those affected by the disaster, thereby doubling the value of those contributions.
“Over the years, CSL and its employees have raised or donated much-needed money, medicines and equipment to areas devastated by sudden crisis such as this one. Our employees have a strong motivation to support disaster appeals and we are proud to honour their commitment by matching their donations in full,” said Mr Perreault.
According to the Australian Red Cross, at least 1,200 people have died, nearly 800 have been injured, more than 160,000 people have been displaced and 6,000 homes were destroyed following the devastating double disaster on 2 October 2018.
For more information about CSL’s support for communities experiencing crisis visit: https://www.csl.com/our-company/in-the-community/disaster-relief
Media Contact
Christina Hickie, Phone: +61 9389 3425/ +61 429 609 762
Christina.hickie@csl.com.au
About CSL Behring
CSL Behring is a global biotherapeutics leader that is driven by its promise to save lives.
Focused on serving patients’ needs by using the latest technologies, we develop and deliver
innovative therapies that are used to treat coagulation disorders, primary immune deficiencies,
hereditary angioedema, inherited respiratory disease, and neurological disorders.
The company's products are also used in cardiac surgery, organ transplantation, burn treatment
and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The
parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs
22,000 people doing business in more than 60 countries.